These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29949609)

  • 1. High CD90 (THY-1) expression positively correlates with cell transformation and worse prognosis in basal-like breast cancer tumors.
    Lobba ARM; Carreira ACO; Cerqueira OLD; Fujita A; DeOcesano-Pereira C; Osorio CAB; Soares FA; Rameshwar P; Sogayar MC
    PLoS One; 2018; 13(6):e0199254. PubMed ID: 29949609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miRNA-135b Contributes to
    Uva P; Cossu-Rocca P; Loi F; Pira G; Murgia L; Orrù S; Floris M; Muroni MR; Sanges F; Carru C; Angius A; De Miglio MR
    Int J Med Sci; 2018; 15(6):536-548. PubMed ID: 29725243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of combination of CD90 and OCT4 for hepatocellular carcinoma after curative resection.
    Zhao RC; Zhou J; Chen KF; Gong J; Liu J; He JY; Guan P; Li B; Qin Y
    Neoplasma; 2016; 63(2):288-98. PubMed ID: 26674131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells.
    Pires MM; Hopkins BD; Saal LH; Parsons RE
    Cancer Biol Ther; 2013 Mar; 14(3):246-53. PubMed ID: 23291982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
    Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
    Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thy-1 predicts poor prognosis and is associated with self-renewal in ovarian cancer.
    Connor EV; Saygin C; Braley C; Wiechert AC; Karunanithi S; Crean-Tate K; Abdul-Karim FW; Michener CM; Rose PG; Lathia JD; Reizes O
    J Ovarian Res; 2019 Nov; 12(1):112. PubMed ID: 31735168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LSD1 overexpression is associated with poor prognosis in basal-like breast cancer, and sensitivity to PARP inhibition.
    Nagasawa S; Sedukhina AS; Nakagawa Y; Maeda I; Kubota M; Ohnuma S; Tsugawa K; Ohta T; Roche-Molina M; Bernal JA; Narváez AJ; Jeyasekharan AD; Sato K
    PLoS One; 2015; 10(2):e0118002. PubMed ID: 25679396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD90 expression in human intrahepatic cholangiocarcinoma is associated with lymph node metastasis and poor prognosis.
    Yamaoka R; Ishii T; Kawai T; Yasuchika K; Miyauchi Y; Kojima H; Katayama H; Ogiso S; Fukumitsu K; Uemoto S
    J Surg Oncol; 2018 Sep; 118(4):664-674. PubMed ID: 30196535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
    Bessette DC; Tilch E; Seidens T; Quinn MC; Wiegmans AP; Shi W; Cocciardi S; McCart-Reed A; Saunus JM; Simpson PT; Grimmond SM; Lakhani SR; Khanna KK; Waddell N; Al-Ejeh F; Chenevix-Trench G
    PLoS One; 2015; 10(5):e0125232. PubMed ID: 25969993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of SHP2 in basal-like and triple-negative breast cells induces basal-to-luminal transition, hormone dependency, and sensitivity to anti-hormone treatment.
    Zhao H; Agazie YM
    BMC Cancer; 2015 Mar; 15():109. PubMed ID: 25885600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SPOCK1 Is a Novel Transforming Growth Factor-β-Induced Myoepithelial Marker That Enhances Invasion and Correlates with Poor Prognosis in Breast Cancer.
    Fan LC; Jeng YM; Lu YT; Lien HC
    PLoS One; 2016; 11(9):e0162933. PubMed ID: 27626636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cripto-1 as a novel therapeutic target for triple negative breast cancer.
    Castro NP; Fedorova-Abrams ND; Merchant AS; Rangel MC; Nagaoka T; Karasawa H; Klauzinska M; Hewitt SM; Biswas K; Sharan SK; Salomon DS
    Oncotarget; 2015 May; 6(14):11910-29. PubMed ID: 26059540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High
    Onaga C; Tamori S; Motomura H; Ozaki A; Matsuda C; Matsuoka I; Fujita T; Nozaki Y; Hara Y; Kawano Y; Harada Y; Sato T; Mano Y; Sato K; Akimoto K
    Anticancer Res; 2021 Jan; 41(1):43-54. PubMed ID: 33419798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
    Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
    Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolation and characterization of CD105+/CD90+ subpopulation in breast cancer MDA-MB-231 cell line.
    Wang X; Liu Y; Zhou K; Zhang G; Wang F; Ren J
    Int J Clin Exp Pathol; 2015; 8(5):5105-12. PubMed ID: 26191205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.
    Hochgräfe F; Zhang L; O'Toole SA; Browne BC; Pinese M; Porta Cubas A; Lehrbach GM; Croucher DR; Rickwood D; Boulghourjian A; Shearer R; Nair R; Swarbrick A; Faratian D; Mullen P; Harrison DJ; Biankin AV; Sutherland RL; Raftery MJ; Daly RJ
    Cancer Res; 2010 Nov; 70(22):9391-401. PubMed ID: 20861192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer.
    Ren X; Yuan L; Shen S; Wu H; Lu J; Liang Z
    Tumour Biol; 2016 Aug; 37(8):11385-95. PubMed ID: 26968553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling.
    Jiang HL; Sun HF; Gao SP; Li LD; Hu X; Wu J; Jin W
    Oncotarget; 2015 Jun; 6(18):16352-65. PubMed ID: 25970785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Annexin A1 Preferentially Predicts Poor Prognosis of Basal-Like Breast Cancer Patients by Activating mTOR-S6 Signaling.
    Bhardwaj A; Ganesan N; Tachibana K; Rajapakshe K; Albarracin CT; Gunaratne PH; Coarfa C; Bedrosian I
    PLoS One; 2015; 10(5):e0127678. PubMed ID: 26000884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD90 Expression Controls Migration and Predicts Dasatinib Response in Glioblastoma.
    Avril T; Etcheverry A; Pineau R; Obacz J; Jegou G; Jouan F; Le Reste PJ; Hatami M; Colen RR; Carlson BL; Decker PA; Sarkaria JN; Vauléon E; Chiforeanu DC; Clavreul A; Mosser J; Chevet E; Quillien V
    Clin Cancer Res; 2017 Dec; 23(23):7360-7374. PubMed ID: 28939749
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.